| 乳腺癌靶向治疗药物的不良反应及其防治 |
| |
| 引用本文： | 张晓清,刘鹏熙.乳腺癌靶向治疗药物的不良反应及其防治[J].国际肿瘤学杂志,2009,36(4). |
| |
| 作者姓名： | 张晓清 刘鹏熙 |
| |
| 作者单位： | 广州中医药大学第二附属医院(广东省中医院)乳腺科,510120 |
| |
| 摘 要： | 目前研究较多的乳腺癌靶向治疗药物有曲妥珠单抗、贝伐单抗和拉帕替尼.临床试验证实上述药物的不良反应主要表现为心血管系统、肾脏和皮肤等的损害.
|
| 关 键 词： | 乳腺肿瘤 抗体 单克隆 |
Adverse reactions of targeted agents and their prevention and treatment in breast carcinoma |
| |
| Abstract: | Targeted agents that have been used most in breast carcinoma treatment include trastuzum-ab,bevacizumab and lapatinib. Clinical trials have proved that their side effects mainly include the damages of cardiovascular system, kidney, skin, and etc. |
| |
| Keywords: | Breast neoplasms Antibodies monoclonal |
| 本文献已被 万方数据 等数据库收录！ |
|
